Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

Source:http://linkedlifedata.com/resource/pubmed/id/14665609

J. Clin. Oncol. 2004 Jan 1 22 1 53-61

Download in:

View as

General Info

PMID
14665609